Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI ) by John F. Heerdink, Jr. 4 days ago Read more 🚀 Register to Join “Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach” – (Friday, August 21 at 8:30am PT) by John F. Heerdink, Jr. August 20, 2026 Read more Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA ) by John F. Heerdink, Jr. August 19, 2026 Read more Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK ) by John F. Heerdink, Jr. August 17, 2026 Read more Eupraxia Pharmaceuticals: A Clinical-Stage Biotech Where the Data Are Starting to Do the Talking -( $EPRX $SNY ) by John F. Heerdink, Jr. August 13, 2026 Read more Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI ) by John F. Heerdink, Jr. August 11, 2026 Read more The Million‑Patient Question: Is Eupraxia’s EP‑104GI Ready To Turn EoE Endoscopy Into A Business Model? -( $EPRX $SNY $XBI ) by John F. Heerdink, Jr. July 30, 2026 Read more The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY ) by John F. Heerdink, Jr. July 20, 2026 Read more Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI ) by John F. Heerdink, Jr. July 13, 2026 Read more Eupraxia’s Board Gets A Major Upgrade: Why EPRX Is Suddenly On Grown‑Up Biotech Lists -( $EPRX $IBB $SNY $XBI ) by John F. Heerdink, Jr. July 7, 2026 Read more Read more
